背景:长-COVID(LC)包括在初次SARS-CoV-2感染后持续数月的各种症状。症状可能使人衰弱,并影响LC患者及其家人的生活质量。虽然LC的症状有很好的描述,LC的病因尚不清楚,因此,患者可能被诊断不足。因此,LC特异性生物标志物的鉴定对于综合征的诊断和临床管理是至关重要的。本范围审查描述了迄今为止已鉴定的分子和细胞生物标志物,可用于诊断或预测LC。
方法:本综述使用JoannaBriggsInstitute(JBI)的范围评价方法进行。在MEDLINE和EMBASE数据库中进行了搜索,以及在原始研究的灰色文献中,直到10月5日,2022年,报告在有LC症状的参与者中发现的生物标志物(来自所有年龄段,种族,和性别),之前感染过SARS-CoV-2.非英语学习,横断面研究,没有对照组的研究,和预打印被排除。两名审稿人独立评估了这些研究,提取的人口数据和相关的生物标志物。
结果:确定了23项队列研究,涉及2163例LC患者[中位年龄51.8岁,以女性为主(61.10%),白色(75%)和未接种疫苗(99%)]。共鉴定出239个候选生物标志物,主要由免疫细胞组成,免疫球蛋白,细胞因子,和其他血浆蛋白。作者对239个候选生物标志物中的19个进行了评估,通过接收器工作特性(ROC)曲线。
结论:已经提出了用于LC的多种细胞和分子生物标志物。应优先考虑独立样品中候选生物标志物的验证。适度报道的表现(特别是在大型研究中)表明LC可能包括许多不同的病因,应该探索,例如,通过按症状群和/或性别分层。
背景:Tebbutt博士已获得加拿大卫生研究院(177747)的资助,以进行这项工作。资金来源没有参与这次范围界定审查,或决定将本手稿提交出版。
BACKGROUND: Long-COVID (LC) encompasses diverse symptoms lasting months after the initial SARS-CoV-2 infection. Symptoms can be debilitating and affect the quality of life of individuals with LC and their families. Although the symptoms of LC are well described, the aetiology of LC remains unclear, and consequently, patients may be underdiagnosed. Identification of LC specific biomarkers is therefore paramount for the diagnosis and clinical management of the syndrome. This scoping review describes the molecular and cellular biomarkers that have been identified to date with potential use for diagnosis or prediction of LC.
METHODS: This review was conducted using the Joanna Briggs Institute (JBI) Methodology for Scoping Reviews. A search was executed in the MEDLINE and EMBASE databases, as well as in the grey literature for original studies, published until October 5th, 2022, reporting biomarkers identified in participants with LC symptoms (from all ages, ethnicities, and sex), with a previous infection of SARS-CoV-2. Non-English studies, cross-sectional studies, studies without a control group, and pre-prints were excluded. Two reviewers independently evaluated the studies, extracted population data and associated biomarkers.
RESULTS: 23 cohort studies were identified, involving 2163 LC patients [median age 51.8 years, predominantly female sex (61.10%), white (75%), and non-vaccinated (99%)]. A total of 239 candidate biomarkers were identified, consisting mainly of immune cells, immunoglobulins, cytokines, and other plasma proteins. 19 of the 239 candidate biomarkers identified were evaluated by the authors, by means of receiver operating characteristic (ROC) curves.
CONCLUSIONS: Diverse cellular and molecular biomarkers for LC have been proposed. Validation of candidate biomarkers in independent samples should be prioritized. Modest reported performance (particularly in larger studies) suggests LC may encompass many distinct aetiologies, which should be explored e.g., by stratifying by symptom clusters and/or sex.
BACKGROUND: Dr. Tebbutt has received funding from the Canadian Institutes of Health Research (177747) to conduct this work. The funding source was not involved in this scoping review, or in the decision to submit this manuscript for publication.